NCT04011293View on ClinicalTrials.gov

A Clinical Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Injection (CNCT19) in the Treatment of Cluster of Differentiation 19 (CD19) Positive Relapsed or Refractory B Cell Malignancies

EARLY_PHASE1UnknownINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

July 31, 2019

Primary Completion Date

July 31, 2020

Study Completion Date

April 30, 2022

Conditions
Relapsed or Refractory Hematological Malignancies
Interventions
BIOLOGICAL

CNCT19

0.5 to 4 x 10\^6 autologous CNCT19 transduced cells per kg body weight, with a maximum dose of 4 x 10\^8 autologous CNCT19 transduced cells via intravenous infusion.

Trial Locations (1)

250012

RECRUITING

Qilu Hospital of Shandong University, Jinan

Sponsors
All Listed Sponsors
collaborator

Juventas Cell Therapy Ltd.

INDUSTRY

lead

Shandong University

OTHER

NCT04011293 - A Clinical Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Injection (CNCT19) in the Treatment of Cluster of Differentiation 19 (CD19) Positive Relapsed or Refractory B Cell Malignancies | Biotech Hunter | Biotech Hunter